Skip To Main Content
Vanan Magimairajan on Muck Rack

Vanan Magimairajan

As seen in: Journal of Clinical Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vanan

Contact Vanan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency

|
By Daniele Merico, Vijay Ramaswamy, Gary Mason, Michael Walsh Verified, Michael Osborn, Michael Sullivan, Lindsay Peterson, Sunil Patel, Jeffrey Atkinson, Michael Taylor Verified, David Malkin, Steffen Albrecht, Cynthia Hawkins, Adam Shlien, Eric Bouffet, Valérie Larouche, Brittany B. Campbell, Richard de Borja, Melyssa Aronson, Carol Durno, Joerg Krueger, Vanja Cabric, Nataliya Zhukova, Roula Farah, Samina Afzal, Michal Yalon, Gideon Rechavi, Vanan Magimairajan, Shlomi Constantini, Rina Dvir, Ronit Elhasid, Alyssa Reddy, Jordan Hansford, Andrew Dodgshun, Nancy Klauber-Demore, Scott Lindhorst, Zane Cohen, Rachel Laframboise, Peter Dirks, Roy W. R. Dudley, Nada Jabado
| Journal of Clinical Oncology Verified
Patients and Methods We performed exome sequencing and neoantigen prediction on 37 bMMRD cancers and compared them with childhood and adult brain neoplasms. Neoantigen prediction bMMRD GBM was compared with responsive adult cancers from multiple tissues. Two siblings with recurrent multifocal bMMRD GBM were treated with the immune checkpoint inhibitor nivolumab. Results All malignant tumors (n = 32) were hypermutant.
Open in Who Shared Issue with article?
See all 1 articles